CA-TRILINK-BIOTECH
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Extends HEVC Advance Rate Increase Deadline27.1.2026 02:00:00 CET | Press release
Provides New Licensees the Opportunity to Join at Current Royalty Rates Access Advance LLC today announced that the Licensors of HEVC Advance have approved an extension of the deadline for new Licensees to secure current royalty rates and caps through 2030. Companies that become Licensees of the HEVC Advance program on or before June 30, 2026 will secure current royalty rates for both ongoing royalties and calculation of royalties for past sales. This is a temporary postponement of the 25% increase in rates and caps applicable to Licensees who sign up after the previous December 31, 2025 deadline. The extension also applies to the Multi-Codec Bridging Agreement ("MCBA"), which provides a single discounted royalty rate structure for Licensees in both the HEVC Advance Patent Pool and the VVC Advance Patent Pool. Licensees who execute the MCBA by June 30, 2026 will benefit from royalty caps that match the royalty caps for the VVC Advance program. The extension follows Access Advance's rec
ANTA Sports to Acquire 29% Stake in PUMA, Further Strengthening Globalization Strategy27.1.2026 01:17:00 CET | Press release
Accelerates multi-brand globalization strategy and enhances ANTA’s global reach and competitivenessBrings proven growth track record to help unlock PUMA’s potential globally including in ChinaSupports PUMA’s management, strategy, brand autonomy and identityHas no current plans to make a takeover offer for PUMA ANTA Sports Products Limited (“ANTA Sports” or the “Company,” stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the “Group”), today announced it has reached a share purchase agreement with Groupe Artémis, the investment company of the Pinault family, to acquire a 29.06% stake in PUMA SE, the company behind iconic global sports brand PUMA. The stake is valued at EUR 1.5 billion in cash. The transaction marks a significant step in ANTA Sports’ globalization strategy, further enhancing its reach, recognition and competitiveness in the global sporting goods market. The transaction is expected to close by the end of 2026, subject to relevant re
MSCI to Consult on a Potential Reclassification of Greece to Developed Market status27.1.2026 00:15:00 CET | Press release
MSCI Inc. (NYSE: MSCI) announced today the launch of a consultation on a proposal for the potential reclassification of Greece from Emerging Market status to Developed Market status in one step, with implementation targeted for the August 2026 Index Review. As part of the MSCI 2025 Market Classification Review, MSCI acknowledged that the Greek market made progress in aligning with the accessibility standards commonly observed in Developed Markets in Europe and that Greece also meets the Economic Development criteria for Developed Market status. However, at the time, Greece did not meet the Size and Liquidity persistency rule, which requires a minimum number of five companies to meet Developed Market Standard Index criteria over each of the last eight Index Reviews to consider an upward reclassification. MSCI treats European countries classified as Developed Markets as a single entity for index construction and maintenance purposes. This approach reflects the high degree of integration
The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More27.1.2026 00:14:00 CET | Press release
Love is in the air at the “World’s Most Romantic Building.” The Empire State Building (ESB) today announced its romantic Valentine’s Day plans for couples in NYC, which include an over-the-top date night, Paint ‘n Pour classes, romantic movie screenings, a sunrise experience, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126953627/en/ The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More “The Empire State Building Observation Deck has played a role in countless love stories throughout its 95-year history, from Hollywood movies to first dates and proposals,” said Dan Rogoski, observatory general manager. “Our world-famous Observatory Experience is the top NYC attraction for couples to make unforgettable memories on Valentine’s Day.” Empire for Two: For the third
Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 202626.1.2026 19:46:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on February 19, 2026. The company will host a conference call and webcast on that date to discuss the fourth quarter and fiscal year 2025 results and the 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126188817/en/ Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, In
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom